A. Bohn1, U. Lass1, KA Kreuzer1, H. Oettle1, CA Schmidt1· 2 Zusammenfassung: Die
Diagnose der minimalen Resterkrankung (MRD) bei Leukämien wurde in der …

A high percentage of patients with leukemia, lymphoma, and solid tumors achieve a
complete clinical remission after initial treatment, but the majority of these patients will finally …

Over the past two decades substantial progress has been made in the therapy of human
leukemias. This development can be illustrated by the success in the treatment of the most …

Despite advances in the treatment of human hematological malignancies, a significant
proportion of patients relapse, usually with the same malignant clone found at diagnosis …

Over the past two decades impressive advances have been achieved in the treatment of
human leukemia. However, disease relapse following successful remission induction …

Despite impressive advances in the treatment of acute lymphoblastic leukemia (ALL),
disease relapse following successful remission induction still poses a significant clinical …

Significant progress has been achieved in the treatment of human leukemias by the
introduction of modern chemotherapeutic strategies and bone marrow transplantation …

Current induction therapies for acute and chronic leukemias and the lymphomas have
achieved significant complete remission rates. Despite this initial success, disease …

The detection of minimal residual disease (MRD) represents a major goal in leukemias with
great potential applications: identification of patients at high risk of relapse, earlier detection …

The source of relapse in patients who achieve complete clinical remission is residual cancer
cells that number below the limits of detection using standard diagnostic techniques …